{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T21:48:30Z","timestamp":1782078510474,"version":"3.54.5"},"reference-count":60,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"research grants provided by the Headache Center, University of Perugia"},{"name":"Ricerca Corrente 2025 - Italian Ministry of Health - to PC, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) play a crucial role in migraine pathophysiology. In recent years, anti-CGRP(R) monoclonal antibodies (mAbs) have emerged as the first targeted and highly effective therapy for migraine. This study aimed to assess any changes in plasma CGRP levels following prophylactic treatment with anti-CGRP(R) mAbs and to compare CGRP dynamics between anti-receptor (erenumab) and anti-ligand (galcanezumab, fremanezumab) therapies. Secondary objectives were: (i) to evaluate changes in VIP and PACAP plasma levels following treatment with anti-CGRP(R) mAbs and (ii) to investigate whether baseline or post-treatment plasma levels of CGRP, VIP and PACAP were associated with clinical response to anti-CGRP(R) monoclonal antibody therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between February 2022 and February 2023, we enrolled 56 migraine patients who initiated prophylaxis with either erenumab (26 patients), galcanezumab (16 patients) or fremanezumab (14 patients). Responders were defined as those achieving a \u226550% reduction in monthly migraine days after six months. Blood samples were collected at baseline and at each follow-up visit (baseline, T0; three months, T1; six months, T2; 12 months, T3). Plasma levels of CGRP, VIP and PACAP were measured using a validated radioimmunoassay and commercially available enzyme-linked immunosorbent assay kits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 80.3% (45 out of 56) of patients responded to anti-CGRP(R) mAbs. No correlation was found between baseline CGRP, VIP and PACAP plasma levels and clinical response to anti-CGRP(R) mAbs therapy. Regarding CGRP trend, significant differences were found between patients treated with the anti-receptor monoclonal antibody (erenumab) and those receiving anti-ligand therapies. In patients treated with erenumab, CGRP levels did not show a significant change over the treatment period (T1\u2013T3), whereas, in the galcanezumab group, CGRP levels significantly decreased as early as T1 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.01). CGRP longitudinal assessment of the fremanezumab group were excluded due to assay interference with the drug. VIP and PACAP plasma levels remained stable over time for all treatments, with no significant differences between responders and non-responders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Galcanezumab reduced CGRP plasmatic levels already after three months, whereas erenumab did not affect significantly CGRP plasmatic levels. VIP and PACAP levels were not influenced by the therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024261429802","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:44:43Z","timestamp":1781703883000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies treatment"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1169-3258","authenticated-orcid":false,"given":"Davide","family":"Chiasserini","sequence":"first","affiliation":[{"name":"Section of Physiology and Biochemistry, University of Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2738-9262","authenticated-orcid":false,"given":"Alessia","family":"Bellotti","sequence":"additional","affiliation":[{"name":"Headache Center, Department of Neurology, Neurocenter of Southern Switzerland, EOC"},{"name":"University of Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3148-9568","authenticated-orcid":false,"given":"Alfredo","family":"Megaro","sequence":"additional","affiliation":[{"name":"University of Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1030-9429","authenticated-orcid":false,"given":"Giuseppe","family":"Tringali","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli-IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1928-1928","authenticated-orcid":false,"given":"Ilenia","family":"Corbelli","sequence":"additional","affiliation":[{"name":"University of Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2311-4918","authenticated-orcid":false,"given":"Elena","family":"Cresta","sequence":"additional","affiliation":[{"name":"University of Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6410-9765","authenticated-orcid":false,"given":"Valeria","family":"Teti","sequence":"additional","affiliation":[{"name":"University of Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4360-4627","authenticated-orcid":false,"given":"Daniela","family":"Fruttini","sequence":"additional","affiliation":[{"name":"University of Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0326-5509","authenticated-orcid":false,"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[{"name":"Sense Organs and Thorax - Fondazione Policlinico Universitario Agostino Gemelli IRCCS"},{"name":"Department of Neuroscience, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4424-650X","authenticated-orcid":false,"given":"Pierluigi","family":"Navarra","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli-IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-3967","authenticated-orcid":false,"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[{"name":"University of Perugia"},{"name":"University of Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2202-1369","authenticated-orcid":false,"given":"Paola","family":"Sarchielli","sequence":"additional","affiliation":[{"name":"University of Perugia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30435-0"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cne.20688"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0373-15.2015"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01807.x"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa7557"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2014.01.004"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413483931"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.113"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn307"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414535111"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12372"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-009-0112-8"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00294.x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a6cb72"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13302"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.105900"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007497"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00305-5"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000310645.31020.b1"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410379890"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1389-9457(00)00065-4"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01193-4"},{"key":"e_1_3_3_26_2","first-page":"293","article-title":"Reduction of plasma CGRP levels in migraine patients treated with erenumab or galcanezumab","volume":"78","author":"Garc\u00eda-Est\u00e9vez DA","year":"2024","unstructured":"Garc\u00eda-Est\u00e9vez DA, Juanatey-Garc\u00eda A, Rodr\u00edguez-Garrido J, et al. Reduction of plasma CGRP levels in migraine patients treated with erenumab or galcanezumab. Rev Neurol 2024; 78: 293\u2013294. English, Spanish. doi: 10.33588\/rn.7810.2023317.","journal-title":"Rev Neurol"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2023-0659"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01354.x"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v067.i01"},{"key":"e_1_3_3_30_2","unstructured":"Lenth R Piaskowski J. emmeans: Estimated marginal means aka least-squares means. R package version 2.0.2. 2026. Available at: https:\/\/rvlenth.github.io\/emmeans\/."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14096"},{"key":"e_1_3_3_32_2","first-page":"83","article-title":"Super- and absolute responders to anti-cgrp monoclonal antibodies in migraine: a one-year multicenter, prospective, observational study","volume":"272","author":"Barbanti P","year":"2025","unstructured":"Barbanti P, Aurilia C, Fiorentini G, et al. Super- and absolute responders to anti-cgrp monoclonal antibodies in migraine: a one-year multicenter, prospective, observational study. J Neurol 2025; 272: 83.","journal-title":"J Neurol"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12103-4"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14640"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01867-3"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26658"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.15011"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1995.1505384.x"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00146.x"},{"key":"e_1_3_3_40_2","article-title":"Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders","volume":"26","author":"Sarchielli P","unstructured":"Sarchielli P, Pini LA, Zanchin G, et al. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia 0000; 26: 257-.","journal-title":"Cephalalgia"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04189.x"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01483-z"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2010.01717.x"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-020-05781-0"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000119"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010740"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01421-z"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2023.103531"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01394-0"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14903"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01567-4"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells12222649"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1811966"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2024.2317778"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12949"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416653232"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211040467"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01769-4"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010293"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251363560"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.18039.1"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261429802","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024261429802","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261429802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T21:33:34Z","timestamp":1782077614000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024261429802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/03331024261429802"],"URL":"https:\/\/doi.org\/10.1177\/03331024261429802","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"03331024261429802"}}